Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene a

Media contact:




Investor contact:




...

Related Keywords

Spain , United States , China , Belgium , Beerse , Region Flamande , Chinese , American , Edmond Chan , Jenni Mildon , Ciltacabtagene Autoleucel , European Commission Grants Conditional Approval , Legend Biotech United States Inc , Janssen Biotech Inc , Drug Administration , American Society Of Clinical Oncology , European Commission , Janssen Cilag International , Chinese Company Legend Biotech To Develop Investigational , American Cancer Society , Committee For Orphan Medicinal Products , Janssen Research Development , Johnson Company , Johnson , European Union , European Medicines Agency , Exchange Commission , Cilag International , Area Lead Haematology , Johnson Innovative , New England Journal , Professor Jes , San Miguel , Translational Medicine , Universidad De Navarra , Jordan Schecter , Vice President , Disease Area Leader , Multiple Myeloma , Orphan Medicinal Products , Product Characteristics , Janssen Biotech , Legend Biotech United States , Innovative Medicine , Janssen Research , Private Securities Litigation Reform Act , Janssen Pharmaceutica , Janssen Cilag Limited , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Cancer Information , Refractory Multiple Myeloma , Available Therapies , Clinical Scenarios Encountered , Study Comparing , Versus Pomalidomide , Participants With Relapsed , Lenalidomide Refractory Multiple Myeloma , Standard Care , Lenalidomide Refractory Multiple , Targeted Treatment Approved , Refractory Multiple Myeloma Who Have Received , Least One Prior Line , Commission Grants Conditional Approval , First Cell Therapy , Refractory Multiple , Clin Cancer Res , Potential Uses , Front Immunol , Janssen Enters Worldwide Collaboration , License Agreement , Chinese Company Legend Biotech , Develop Investigational , Markets ,